Molecular strategies to inhibit HIV-1 replication

Retrovirology

Volumn 2, Issue , 2005, Pages

  Nielsen, Morten Hjuler ^a   Pedersen, Finn Skou ^a   Kjems, Jørgen ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); AMINOOXYPENTANE RANTES; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; APTAMER; CD4 IMMUNOGLOBULIN G2; CHEMOKINE; CHIMERIC PROTEIN; COMPLEMENTARY RNA; CYANOVIRIN N; CYCLOPHILIN 18; CYCLOPHILIN A; DINUCLEOTIDE; GENE PRODUCT; HAMMERHEAD RIBOZYME; HYBRID PROTEIN; INTEGRASE INHIBITOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICRORNA; MONOCLONAL ANTIBODY; NUCLEASE; OLIGONUCLEOTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SHORT HAIRPIN RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LIFE CYCLE; MEDICAL RESEARCH; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NONHUMAN; PROTEIN TARGETING; REVIEW; SUICIDE GENE THERAPY; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 18144403552     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-2-10     Document Type: Review

References (80)

1. Ho DD, Huang Y: The HIV-1 vaccine race. Cell 2002, 110:135-138.
2. Peters BS: The basis for HIV immunotherapeutic vaccines. Vaccine 2001, 20:688-705.
3. Haasnoot PCJ, Cupac D, Berkhout B: Inhibition of virus replication by RNA interference. Journal of Biomedical Science 2003, 10:607-616.
4. Coffin JM: Retroviridae: The viruses and their replication. In Fields Virology Third edition. Edited by: Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott - Raven Publichers; 1996:1767-1830.
5. Joshi S, Singwi S: Potential nuclease-based strategies for HIV gene therapy. Frontiers in Bioscience 2000, 5:556-579.
6. Joshi S, Lamothe B: Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies. Frontiers in Bioscience 2000, 5:527-555.
7. Gottfredsson M, Bohjanen PR: Human immunodeficiency virus type 1 as a target for gene therapy. Frontiers in Bioscience 1997, 2:619-634.
8. Tomaras GD, Greenberg ML: Mechanisms for HIV-1 entry: Current strategies to interfere with this step. Current Infectious Disease Reports 2001, 3:93-99.
9. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TM, Buser R, Wells TNC, Proudfoot AE: I. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science Magazine 1997, 276:276-279.
10. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M Jr, Lifson JD, Salkowitz JR, Rodriquez B, Blauvelt A, Hartley O: Prevention of vaginal SHIV transmission in Rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487.
11. Dewhurst S, Whetter L: Pathogenesis and treatment of HIV-1 infection: Recent developments. Frontiers in Bioscience 1997, 2:148-159.
12. Dragic T: An overview of the determinants of CCR5 and CXCR4 co-receptor function. J General Virol 2001, 82: 1807-1814.
13. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001, 70:777-810.
14. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC: Potent broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001, 75:579-588.
15. Mori T, Boyd MR: Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, Inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrobial Agents and Chemotherapy 2001, 45:664-672.
16. Spenlehauer C, Kirn A, Aubertin A, Moog C: Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: Investigation of the mechanism of inhibition. J Virol 2001, 75:2235-2245.
17. Yarovinsky F, Andersen JF, King LR, Caspar P, Aliberti J, Golding H, Sher A: Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii. J Biol Chem 2004, 279:53635-53642.
18. Bunnell BA, Morgan RA: Gene therapy for infectious diseases. Clinical Microbiol Reviews 1998, 11:42-56.
19. Gilboa E, Smith C: Gene therapy for infectious diseases: the AIDS model. TIG 1994, 10:139-144.
20. Lawrence D: RNAi could hold promise in the treatment of HIV. The Lancet 2002, 359:2007.
21. Martinez MA, Gutiérrez A, Armand-Ugón M, Blanco J, Parera M, Gómez J, Clotet B, Esté JA: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002, 16:2385-2390.
22. Martinez MA, Clotet B, Esté JA: RNA interference of HIV replication. TRENDS in immunology 2002, 23:559-561.
23. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee S, Collman RG, Lieberman J, Shankar P, Sharp PA: siRNA-directed inhibition of HIV-1 infection. Nature Medicine 2002, 8: 681-686.
24. Wang Q, Nie Q, Feng Z: RNA interference: Antiviral weapon and beyond. World Journal of Gastroenterology 2003, 9(8): 1657-1661.
25. Heguy A: Inhibition of the HIV Rev transactivator: A new target for therapeutic intervention. Frontiers in Bioscience 1997, 2:283-297.
26. Park W, Miyano-Kurosaki N, Hayafune M, Nakajima E, Matsuzaki T, Shimada F, Takaku H: Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference. Nucleic Acids Res 2000, 30:4830-4835.
27. Cammack N: The potential for HIV fusion inhibition. Current opinion in infectious diseases 2001, 14:C13-16.
28. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med 1998, 4:1302-1307.
29. Lee S, Garza L, Yao J, Notkins AL, Zhou P: A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: A new way to fight HIV. The Journal of Immunology 2004, 173:4618-4626.
30. Divita G, Restle T, Goody RS, Chermann J, Baillon JG: Inhibition of human immunodefiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. JBC 1994, 269:13080-13083.
31. Joshi P, Prasad VR: Potent inhibition of human immunodeficiency virus type 1 replication by template analogue reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 2002, 76: 6545-6557.
32. Nickens D, Gordon J, Burke DH: In vivo inhibition of HIV-1 reverse transcriptase by RNA aptamers. Indiana University, Department of Chemistry.
33. Osborne SE, Matsumura I, Ellington AD: Aptamers as therapeutic and diagnostic reagents: problems and prospects. Current opinion in chemical biology 1997, 1:5-9.
34. Jacque J, Triques K, Stevenson M: Modulation of HIV-1 replication by RNA interference. NATURE 2002, 418:435-438.
35. Surabhi RM, Gaynor RB: RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J Virol 2002, 76:12963-12973.
36. Giordano V, Jin D, Rekosh D, Jeang KT: Intravirion targeting of a functional anti-human immunodeficiency virus ribozyme directed to pol. Virology 2000, 267:174-184.
37. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schümperli D: Inhibition of HIV-1 multiplication by anti-sense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Research 2004, 32:3752-3759.
38. Trkola A: HIV-host interactions: vital to the virus and key to its inhibition. Current Opinion in Microbiology 2004, 7:407-411.
39. Yung E, Sorin M, Pal A, Craig E, Morozov A, Delattre O, Kappes J, Ott D, Kalpana GV: Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nature Med 2001, 7:920-926.
40. Zhu K, Cordeiro ML, Atienza J, Robinson WE, Chow SA: Irreversible inhibition of human immunodefiency virus type 1 integrase by dicaffeoylquinic acids. J Virol 1999, 73:3309-3316.
41. Nair V: HIV integrase as a target for antiviral chemotherapy. Rev Med Virol 2002, 12:179-193.
42. Capodici J, Karikó K, Weissman D: Inhibition of HIV-1 infection by small interfering RNA mediated RNA interference. The Journal of Immunology 2002, 169:5196-5201.
43. Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. Journal of Leukocyte Biologi 2003, 74:736-749.
44. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR: Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci USA Biochemistry 1999, 96:7791-7796.
45. Joshi S, Ding S, Noronha J: Co-packaging of sense and anti-sense RNAs: a novel strategy for blocking HIV-1 replication. Nucleic Acids Research 1998, 26:3270-3278.
46. Hwang S, Tamilarasu N, Kibler K, Cao H, Ali A, Ping Y, Jeang KT, Rana TM: Discovery of a small molecule tat-trans-activationresponsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. The Journal of Biological Chemistry 2003, 278:39092-39103.
47. Mischiati C, Finotti A, Serini A, Boschetti S, Baraldi PG, Romagnoli R, Feriotto G, Jeang KT, Bianchi N, Borgatti M, Gambari R: Binding of hybrid molecules containing pyrrolo [2,1-c][1,4]benzodiazepine (PBD) and oligopyrrolo carriers to the human immunodeficiency type 1 virus TAR-RNA. Biochemical Pharmacology 2004, 67:401-410.
48. Mischiati C, Jeang KT, Feriotto G, Breda L, Borgatti M, Bianchi N, Gambari R: Aromatic polyamidines inhibiting the tat-induced HIV-1 transcription recognize structured TAR-RNA. Antisense & Nucleic Acid Drug Development 2001, 11:209-217.
49. Coburn GA, Cullen BR: Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 2002, 76:9225-9231.
50. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B: Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Research 2004, 32: 1154-1158.
51. Browning CM, Cagnon L, Good PD, Rossi J, Engelke DR, Markovitz DM: Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 Tat activation-response RNA decoy. J Virol 1999, 73:5191-5195.
52. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004, 78: 2601-2605.
53. Chiu Y, Cao H, Jacque J, Stevenson M, Rana TM: Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol 2004, 78:2517-2529.
54. Si Q, Cosenza MA, Kim M, Zhao M, Brownlee M, Goldstein H, Lee SC: A novel action of minocycline: Inhibition of human immunodeficiency virus type 1 infection in microglia. Journal of NeuroVirology 2004, 10:284-292.
55. Askjaer P, Jensen TH, Nilsson J, Englmeier L, Kjems J: The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. The Journal of Biomedical Chemistry 1998, 273: 33414-33422.
56. Bogerd HP, Echarri A, Ross TM, Cullen BR: Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. J Virol 1998, 72:8627-8635.
57. Kjems J, Askjær P: Rev protein and its cellular partners. Advances in Pharmacology 2000, 48:251-298.
58. Pollard VW, Malim MH: The HIV-1 Rev protein. Annu Rev Microbiol 1998, 52:491-532.
59. Bonyhadi ML, Moss K, Voytovich A, Auten J, Kalfoglou C, Plavec I, Forestell S, Su L, Böhnlein E, Kaneshima H: RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 1997, 71:4707-4716.
60. Reddy TR, Xu W, Mau JKL, Goodwin CD, Suhasini M, Tang H, Frimpong K, Rose DW, Wong-Staal F: Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev. Nature Med 1999, 5:635-642.
61. Lee NS, Dohjima T, Bauer G, Li H, Li M, Ehsani A, Salvaterra P, Rossi J: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature biotech 2002, 20:500-505.
62. Omoto S, Ito M, Tsutsumi Y, Ichikawa Y, Okuyama H, Andi Brisibe E, Saksena NK, Fujii YR: HIV-1 nef suppression by virally encoded microRNA. Retrovirology 2004, 1:44.
63. Bennasser Y, Le S, Yeung ML, Jeang KT: HIV-1 encoded candidate micro-RNAs and their cellular targets. Retrovirology 2004, 1:43.
64. Gelderblom HR: Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 1991, 5: 617-637.
65. Zhang Y, Quan H, Love Z, Barklis E: Analysis of the assembly function of the human immunodeficiency virus type 1 Gag protein nucleocapsid domain. J Virol 1998, 72:1782-1789.
66. D'aloja P, Olivetta E, Bona R, Nappi F, Pedacchia D, Pugliese K, Ferrari G, Verani P, Federico M: gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: Identification of novel HIV-1-inhibiting viral protein mutants. J Virol 1998, 72: 4308-4319.
67. Miller RJ, Cairns JS, Bridges S, Sarver N: Human immunodeficiency virus and AIDS: Insights from animal Lentiviruses. J Virol 2000, 74:7187-7195.
68. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003, 300:1112.
69. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
70. Veres G, Junker U, Baker J, Barske C, Kalfoglou C, Ilves H, Escaich S, Kaneshima H, Böhnlein E: Comparative analyses of intracellularly expressed anti-sense RNAs as inhibitors of immunodeficiency virus type 1 replication. J Virol 1998, 72: 1894-1901.
71. Carter CA: Tsg 101: HIV-1's ticket to ride. Trends in Microbiology 2002, 10:203-205.
72. Kibler KV, Miyazato A, Yedavalli VRK, Dayton AI, Jacobs BL, Dapolito G, Kim S, Jeang KT: Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. The Journal of Biological Chemistry 2004, 249: 49055-49063.
73. Fung HB, Kirschenbaum HL, Hameed R: Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor. Clinical Therapeutics 2000, 22:549-572.
74. Kobinger GP, Borsetti A, Nie Z, Mercier J, Daniel N, Göttlinger HG, Cohen EA: Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J Virol 1998, 72:5441-5448.
75. Gervaix A, Li X, Kraus G, Wong-Staal F: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 1997, 71:3048-3053.
76. Lisziewicz J, Sun D, Trapnell B, Thomson M, Chang H, Ensoli B, Peng B: An autoregulated dual-function anti-tat gene for human immunodeficiency virus type 1 gene therapy. J Virol 1995, 69: 206-212.
77. Harrison GS, Maxwell F, Long CJ, Rosen CA, Glode LM, Maxwell IH: Activation of a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev proteins in transfected cells. Hum Gene Ther 1991, 2(1):53-60.
78. Smith SM, Markham RB, Jeang KT: Conditional reduction of human immunodeficiency virus type 1 replication by a gainof-herpes simplex virus 1 thymidine kinase function. Proc Natl Acad Sci USA 1996, 93:7955-7960.
79. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF: Killing HIV-infekted cells by transduction with an HIV proteaseactivated caspase-3 protein. Nature Med 1999, 5:29-33.
80. Michael NL, Moore JP: HIV-1 entry inhibitors: Evading the issue. Nature Med 1999, 5:740-741.